Abstract 146P
Background
Esophageal cancer is an aggressive cancer with a poor prognosis. Prognostic factors are mainly based on cancer staging. HSPs are molecular chaperones that help protect against stress, often overexpressed in esophageal cancer. However, the prognostic significance and regulatory factors, such as HSF1 and CHIP, are poorly understood. To address the gap, a meta-analysis was conducted to investigate the relationship between HSP expression, prognosis-related factors, and clinicopathological features of esophageal cancer.
Methods
A systematic review was conducted by two reviewers on patients with esophageal cancer until Feb 15 2023. The study compared patients with positive HSP proteins to HSP-negative patients, analyzing grade of differentiation, lymph node metastasis, tumor depth, distant metastasis, and overall survival. HSP were stratified by HSP family, and summary risk difference (RD) were calculated using a random-effect model. Statistical heterogeneity was calculated using I2 statistic, and the risk and bias assessment, using the ROBINS-I tool. This study was conducted in accordance with PRISMA statement recommendations.
Results
Final selection comprised 27 studies, with a pooled sample size of 3465 patients. The mean age was 60.7 years old (46-69), with a male predominance. HSP40 and 60 were associated with a higher 3-year overall survival (HSP40 RD: 0.22; 95% CI: 0.09 to 0.35; HSP60 RD: 0.33; 95% CI: 0.17 to 0.50), while HSF1 was associated with a poor 3-year overall survival (RD: -0.22; 95% CI: -0.32 to -0.12). HSF1 was associated with a higher probability of lymph nodal metastasis (RD: -0.16; 95% CI: -0.29 to -0.04). HSP40 was associated with lower probability for lymph nodal dissemination (RD: 0.18; 95% CI: 0.03 to 0.33). HSP were not found to be related to lymph nodal metastasis, tumor depth or distant metastasis. Besides, HSPs were not related to grade of cellular differentiation.
Conclusions
Our systematic review and meta-analysis showed that the expressions of certain families of HSP, such as HSP40 and 60, HSF1 are associated with long-term survival and lymph nodal dissemination in patients with esophageal cancer. These findings support the role of HSP in susceptibility, progression and prognosis in esophageal cancer.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Universidade de São Paulo.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
113P - Evaluation of effects of tissue preservation methods on the proteome abundance through deep proteomics of breast cancer tissue
Presenter: Shashwati parihari
Session: Cocktail & Poster Display session
Resources:
Abstract
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract